相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
E. Martinelli et al.
ANNALS OF ONCOLOGY (2020)
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Carminia M. Della Corte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'
Vincenzo De Falco et al.
ESMO OPEN (2020)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv192, 2018)
D. Planchard et al.
ANNALS OF ONCOLOGY (2019)
Product review: avelumab, an anti-PD-L1 antibody
Julie M. Collins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
Alexander Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Radiotherapy with concurrent Avelumab and Cetuximab as primary treatment in patients with locally advanced squamous cell carcinoma of the head and neck: A phase-IB feasibility trial in patients unfit for cisplatin (NCT02938273).
Joris B. W. Elbers et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Avelumab (anti-PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.
Arun Rajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients
Sriram Srivatsa et al.
GASTROENTEROLOGY (2017)
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis
Sarah Cargnin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
Yuka Inoue et al.
CANCER SCIENCE (2017)
Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer
Masahiro Kitahara et al.
CANCER SCIENCE (2016)
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Sumita Trivedi et al.
CLINICAL CANCER RESEARCH (2016)
Evaluation of antibody- dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients
Cristiana Lo Nigro et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
Roberto Bellucci et al.
ONCOIMMUNOLOGY (2015)
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation
Hanane Lanaya et al.
NATURE CELL BIOLOGY (2014)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
Kenneth J. O'Byrne et al.
LANCET ONCOLOGY (2011)
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
Ulrich Gatzemeier et al.
LANCET ONCOLOGY (2011)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Relationship between CD107a expression and cytotoxic activity
Esin Aktas et al.
CELLULAR IMMUNOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
分享论文
